SAN RAFAEL, Calif.--(BUSINESS WIRE)--Eastbourne Capital Management, L.L.C. today announced that it sent a letter to the Board of Directors of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) earlier this week noting that the arguments put forward on behalf of the incumbent Board have failed to persuade key independent thinkers as evidenced by the unanimous recommendations of the three leading proxy voting advisory services – RiskMetrics Group, Glass Lewis & Co and PROXY Governance – that Amylin shareholders will benefit from new leadership and new directors are needed to oversee the Company’s efforts to become a successful commercial enterprise and that Amylin shareholders should support the shareholder nominees for election to the board at the 2009 Annual Meeting of Shareholders.
